mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
Overview
In the rapidly evolving landscape of therapeutic nucleic acids, messenger RNA (mRNA) has emerged as a revolutionary platform for vaccines and protein replacement therapies. However, the production of mRNA via in vitro transcription (IVT) inevitably generates undesired byproducts, most notably double-stranded RNA (dsRNA). These dsRNA impurities are potent triggers of the innate immune system, recognized by pattern recognition receptors (PRRs) such as Toll-like receptor 3 (TLR3) and melanoma differentiation-associated protein 5 (MDA5).
Uncontrolled levels of residual dsRNA lead to severe inflammatory responses, unintended reactogenicity, and the inhibition of target protein translation, effectively compromising the safety and efficacy of the final drug product. CD BioGlyco provides a comprehensive mRNA residual dsRNA analysis service, utilizing high-precision analytical platforms to ensure your mRNA constructs meet the stringent purity standards.
Key Technologies
- Enzyme-Linked Immunosorbent Assay (ELISA)
We utilize highly specific monoclonal antibodies to detect dsRNA duplexes independent of sequence. This method provides high-throughput capability with a lower limit of quantification (LLOQ) in the picogram per milliliter (pg/mL) range. - Immunoblotting Analysis
This technique is ideal for rapid screening and semi-quantitative assessment. By spotting mRNA samples onto specialized membranes and using chemiluminescent detection, we quickly identify the presence of dsRNA contaminants across multiple batches during process development. - High-Performance Liquid Chromatography (HPLC)
For advanced structural characterization, we utilize single-strand specific nuclease to digest the primary mRNA, leaving only the dsRNA intact. The remaining fragments are then analyzed via reverse-phase HPLC or capillary electrophoresis to determine the exact size and concentration of the impurities.
Precision Monitoring Residual dsRNA for Enhanced mRNA Purity and Safety
At CD BioGlyco, our service scope is meticulously designed to support the entire lifecycle of mRNA-based vaccine development. As a critical component of our mRNA structural characterization offerings, we provide deep-dive analysis into the impurity profiles of various nucleic acid modalities. Our analysis covers:
- Quantitative dsRNA Profiling: Precise determination of dsRNA weight percentage relative to total mRNA.
- Size Distribution Analysis: Identifying whether the dsRNA exists as short abortive transcripts or long antisense duplexes.
- Process-Specific Impurity Tracking: Monitoring dsRNA levels across different in vitro transcription (IVT) conditions, scale-up stages, and purification steps (e.g., chromatography).
- Matrix Interference Mitigation: Specialized protocols to ensure accurate detection within complex lipid nanoparticle (LNP) formulations or high-concentration drug substances.
Workflow
Sample Reception and Quality Assessment
Upon receiving your mRNA samples, our team performs an initial concentration check and integrity assessment using microfluidic electrophoresis. This ensures that the starting material is suitable for high-sensitivity dsRNA detection.
Method Optimization and Calibration
Depending on the mRNA sequence and modification, we optimize buffer conditions and prepare standard curves using certified dsRNA standards to mitigate any potential matrix effects or structural interference.
Primary Quantitative Analysis
The samples undergo sandwich ELISA processing. We perform multiple dilutions to ensure results fall within the linear range of the assay, providing a robust quantitative value for the residual dsRNA content.
Advanced Structural Characterization
For clients requiring detailed impurity profiles, we perform enzymatic digestion of the single-stranded mRNA. The remaining dsRNA is characterized by its migration pattern to distinguish between different types of double-stranded byproducts.
Data Integration and Quality Control
All raw data are processed through our advanced bioinformatics tools. We verify the results against internal controls and industry benchmarks to ensure the accuracy of the reported dsRNA levels.
Comprehensive Technical Reporting
We deliver a detailed report containing quantitative data, representative plots, and expert interpretations regarding the impact of the observed dsRNA levels on your project's goals.
Publication Data
DoI: 10.3390/vaccines12080899
Journal: Vaccine
IF: 3.5
Published: 2024
Results: This study describes the development and application of an automated sandwich ELISA for quantifying residual dsRNA in mRNA vaccines. The assay uses commercial J2/K2 antibodies, achieves <10 ng/mL detection limit, >2000-fold specificity for dsRNA over mRNA, and <15% variability. Automated with liquid handlers, it processes 72 samples/day, reducing analyst time. Optimized to mitigate interference from IVT components like proteinase K/SDS, it performs well across mRNA manufacturing stages (IVT intermediates to purified products). Validated with spike recovery and process comparisons, it supports manufacturing optimization, e.g., identifying dsRNA reduction via N1-Me-pseudo UTP substitution or cellulose purification. This robust, cost-effective tool aids mRNA vaccine quality control.
Fig.1 Quantifying residual dsRNA in mRNA elution samples and IVT samples. (Holland, et al., 2024)
Applications
Applications
mRNA Vaccine Development
Essential for ensuring that vaccines for infectious diseases or oncology do not trigger excessive inflammation, thereby improving the safety profile and enhancing the translation of the target antigen in vivo.
Protein Replacement Therapy Development
Critical for chronic dosing applications where the accumulation of dsRNA-induced cytokines could lead to treatment resistance or adverse systemic immune reactions over long-term therapeutic courses.
Gene Editing Research
Used to verify the purity of mRNA encoding nucleases, ensuring that the cellular response to the mRNA vehicle does not interfere with the delicate gene-editing machinery.
RNAi and Antisense Research
Helps researchers distinguish between the intended biological effect of a duplex and the unintended immune activation caused by process-related dsRNA contaminants during early discovery phases.
Advantages
Superior Sensitivity and Dynamic Range
Our optimized ELISA and HPLC platforms detect dsRNA levels as low as 0.001%, significantly exceeding standard requirements.
Advanced Matrix Management
Our proprietary buffers and specialized sample preparation techniques effectively eliminate interference from nucleotides, DNA templates, or delivery lipids, ensuring the most accurate readings in the industry.
Unmatched Scientific Expertise
Our technicians possess years of experience in nucleic acid chemistry, allowing us to provide not just data, but actionable insights into how to reduce dsRNA during your IVT process.
Rapid and Scalable Throughput
Utilizing automated liquid handling and high-throughput plate readers, CD BioGlyco processes large batches of samples simultaneously, maintaining rapid turnaround times without sacrificing data quality.
Frequently Asked Questions
Customer Review
They identified trace impurities that our in-house blot missed, allowing us to refine our purification process before it became a regulatory hurdle.
— E.R., Leading Biotech Firm
CD BioGlyco provided a detailed dsRNA profile that explained the variability. Their technical support team is incredibly knowledgeable.
— S.T., Pharmaceutical Company
From sample shipment to the final report, the communication was professional and the data was clear. Their ability to handle LNP-encapsulated samples saved us weeks of internal method development.
— Z.G., RNA Institute
Associated Services
CD BioGlyco is your dedicated partner in ensuring the highest purity and safety for your mRNA therapeutics. Our mRNA residual double-stranded rnA (dsRNA) analysis service provides the precision and reliability needed to navigate the complex regulatory pathway of nucleic acid drug development. Please feel free to contact us to discuss your project or request a detailed quotation. Our team of specialists is standing by to assist you with your analytical needs.
Reference
- Holland, D.A.; et al. Development and application of automated sandwich ELISA for quantitating residual dsRNA in mRNA vaccines. Vaccines. 2024, 12(8): 899. (Open Access)